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Abstract
Currently, 1% of the United States population holds 
a diagnosis for celiac disease (CD), however, a more 
recently recognized and possibly related condition, 
“non-celiac gluten sensitivity” (NCGS) has been su-
ggested to affect up to 6% of the United States public. 
While reliable clinical tests for CD exist, diagnosing 
individuals affected by NCGS is still complicated by the 
lack of reliable biomarkers and reliance upon a broad 
set of intestinal and extra intestinal symptoms possibly 
provoked by gluten. NCGS has been proposed to exhibit 
an innate immune response activated by gluten and 
several other wheat proteins. At present, an enormous 
food industry has developed to supply gluten-free 
products (GFP) with GFP sales in 2014 approaching 
$1 billion, with estimations projecting sales to reach 
$2 billion in the year 2020. The enormous demand 
for GFP also reflects a popular misconception among 
consumers that gluten avoidance is part of a healthy 
lifestyle choice. Features of NCGS and other gluten 
related disorders (e.g. , irritable bowel syndrome) call 
for a review of current distinctive diagnostic criteria 
that distinguish each, and identification of biomarkers 
selective or specific for NCGS. The aim of this paper 
is to review our current understanding of NCGS, 
highlighting the remaining challenges and questions 
which may improve its diagnosis and treatment.
Key words: Non-celiac gluten sensitivity; Celiac disease; 
Gluten; Wheat; Gluten related disorder; Gluten free 
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Core tip: Non-celiac gluten sensitivity, a less known 
clinical entity has been estimated to have a prevalence 
of up to 6% in the United States. This review identifies 
the pathophysiology of the disease delineating clearly 
the important components of wheat which play a role 
in its innate immune response. The updated guidelines 
on the diagnosis of this disease is discussed here with a 
bridge to other management strategies apart from the 
gluten free diet that are now being investigated.
Igbinedion SO, Ansari J, Vasikaran A, Gavins FN, Jordan 
P, Boktor M, Alexander JS. Non-celiac gluten sensitivity: 
All wheat attack is not celiac. World J Gastroenterol 2017; 
23(40): 7201-7210  Available from: URL: http://www.wjgnet.
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INTRODUCTION
In the past decade, the consumption of gluten free 
food has become increasingly popular in the Western 
world. A Gallup poll conducted in July 2015 showed 
that 20% of Americans opt for a gluten free diet 
(GFD) while 17% say they avoid gluten free foods[1]. 
Estimates by the nutrition industry indicate that sales 
of gluten-free products (GFPs) had a compound annual 
growth rate of 34% over the five year period ending in 
2014, with annual sales totaling close to $1 billion[2]. 
Current market projections predict sales will again 
soar to approach $2 billion in the year 2020[3]. Market 
research by the Mintel group gives a liberal estimation 
of the sales of products in the gluten-free industry to 
be $11.6 billion in the year ending 2015, an estimated 
136% increase from 2013[4]. The significant increase in 
the retail sales of GFPs is alarming. However, currently 
only approxiately 1% of the United States population 
is diagnosed with celiac disease[5]. Despite this, gluten-
free food consumption is clearly on an exponential 
rise. This enormous allocation of resources reflects 
self-diagnosis for gluten sensitivity and may reflect 
an additional condition described as non-celiac gluten 
sensitivity (NCGS). 
The first comprehensively documented case 
of “gluten sensitivity” (in a non-celiac disease/wh-
eat allergy patient) was reported in 1980[6]. That 
report described eight adult women suffering from 
incapacitating abdominal pain and chronic diarrhea 
which rapidly remitted when a gluten-free diet was 
initiated, with symptomatic relapse after re-exposure 
to a gluten containing diet (GCD). Jejunal biopsies 
performed on these patients, however, failed to 
identify CD-like histopathology, leading to a consensus 
description of these patients as having “gluten-sensitive 
diarrhea without evidence of celiac disease”. This 
was the beginning of the current era of what we now 
consider NCGS. Since then, many subsequent studies 
have attempted more extensive descriptions of NCGS 
to create effective diagnostic criteria and management 
strategies.
In 2011, an international consensus on NCGS re-
ached an agreement on the definition of NCGS, defining 
it as a “non-allergic and non-autoimmune condition in 
which the consumption of gluten can lead to symptoms 
similar to those seen in CD.” NCGS is defined as 
gluten sensitivity because symptoms are relieved by 
gluten withdrawal, and re-appear upon introduction 
to gluten[7]. At least part of the difficulty in handling 
NCGS patients is that essentially, it is often a diagnosis 
by exclusion. First, CD and WA need to be excluded as 
possible diagnoses. Beyond this, NCGS often carries an 
extensive and relatively broad set of symptoms which 
affects diverse organ systems[8]. Symptoms of NCGS 
could be very disabling presenting as gastrointestinal 
and/or extra-intestinal symptoms[9]. The onset of 
NCGS symptoms after gluten consumption can also 
range widely, appearing hours to even days following 
exposure to a GCD; the timing of resolution in NCGS 
symptoms may also vary widely. 
Given that NCGS presentation could resemble CD 
or WA, further research into highlighting their hallmark 
findings is necessary. It is essential now that individuals 
with gluten-related disorders are identified accurately 
and managed appropriately. This is important in order 
to curtail the significant rise in the retail sales of GFPs 
in the food industry as millions of dollars could be 
salvaged given the appropriate diagnosis amongst 
other important reasons. This current review discusses 
our present understanding of NCGS, its differences and 
similarities to CD and other gluten-related disorders, 
etiopathogenesis and management strategies. It is 
important to recognize that NCGS is a distinct disorder 
from CD and it is imperative that it is accurately 
distinguished.
EPIDEMIOLOGY
Despite becoming a more common diagnosis, there is 
currently a paucity of information on NCGS especially 
regarding its actual prevalence in the general population. 
This lack of information reflects the decision of many 
patients to start GFD after self-diagnosis without any 
formal clinical testing or management recommendation 
by their physician. As a result of this ambiguity, 
the prevalence of NCGS has been reported to vary 
enormously from 0.6%-6% in Western populations[10-12]. 
It is unclear how much of the rise in consumption of 
gluten free foods actually reflect a higher prevalence of 
NCGS in the population or the choice to adhere to a 
GFD based on patient’s preferences. 
Despite the lack of accurate epidemiologic mea-
surements of the actual US prevalence of NCGS, data 
in 2009-2010 from the National Health and Nutrition 
Examination Survey (NHANES) showed that of the 
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7762 NHANES participants who were free of celiac 
disease, 49 individuals reported a strict adherence to 
a GFD. This reflects a weighted prevalence of NCGS 
of only 0.55%[11]. Another more recent evaluation of 
the NHANES participants from 2009-2012 separated 
patients into those with CD and those without CD 
consuming a GFD. This study estimated a prevalence 
of NCGS of 0.8% in patients without CD who were 
consuming a GFD[10]. The prevalence in these NHANES 
studies were estimated based on the assessment that 
the individuals without CD avoiding gluten fall under 
the classification of NCGS.
During the period 2004 and 2010, 5896 patients 
were seen at the Center for Celiac Research at the 
University of Maryland. Of these, 347 participants 
met the criteria for diagnosis of “Gluten Sensitivity” 
reflecting about 6% of the patients seen[12]. These 
gluten triggered symptoms included abdominal pain 
(68%), eczema and/or rash (40%); headache (35%); 
“foggy mind” or difficulty focusing (34%); fatigue 
(33%); diarrhea (33%); depression (22%); anemia 
(20%); numbness in the legs, arms or fingers (20%); 
and joint pain (11%)[12]. The proportion of patients 
with NCGS in this study extrapolated to the general 
population estimated an enormous prevalence of 
NCGS compared with that previously seen in prior 
studies. Based on our review, the estimation of the 
prevalence of NCGS ranges widely from 0.6% to 6%, 
a ten-fold difference. As identified, the prevalence of 
NCGS in the general population may exceed that of CD 
- now estimated at 1%[5]. However this appears to be 
a high estimate based solely on symptomatology.
As NCGS is a relatively “new” entity compared to 
CD, it is also unclear whether or to what extent genetic 
or environmental risks might predispose individuals 
to this disorder. Studies have suggested gender 
contributions with the female to male prevalence 
ratio between 3:1[13,14] to 5.4:1[15], indicating a female 
predominance in NCGS. This may however reflect 
the observation that female patients are more prone 
to reporting gluten-related symptoms thus leading 
to referrals for further work-up as seen in a United 
Kingdom study in 2014[16]. There has also been a 
heightened interest in the association of NCGS with 
other medical conditions. An overlap between irritable 
bowel syndrome (IBS) and NCGS has been suggested 
since most of the gastrointestinal symptoms in NCGS 
resemble IBS (similar Rome III criteria), including 
abdominal pain/discomfort, bloating, diarrhea and 
constipation[15]. There is also a debate as to whether 
a GFD can help symptom resolution in IBS after 
excluding CD, as clinical trials have shown that GFD 
can reduce symptoms in patients with diarrhea-
predominant IBS (IBS-D)[17]. Although recent research 
has suggested that a low fermentable oligo-, di-, 
mono-saccharides and polyols (FODMAPs) diet, 
regardless of gluten content, improves symptoms in 
IBS[18]. Given the close symptomatic resemblance 
between NCGS and IBS, prevalence estimates may be 
unclear as patients with NCGS could be mislabeled as 
IBS.
PATHOGENESIS
The pathobiology of NCGS is poorly understood, hotly 
debated and under intense research (Figure 1). NCGS 
potentially involves many triggers as are seen in CD 
and IBS. The initiating event in NCGS mainly involves 
exposure of gut epithelium to gluten containing foods 
leading to immune-mediated and/or non-immune 
mediated responses. Whereas CD shows increased 
gut permeability, NCGS shows a decreased gut solute 
permeability with increased epithelial barrier and 
elevated expression of the tight junctional component 
claudin-4[19-21]. Due to the lack of evidence for T-cell 
involvement and the apparent contribution from toll-like 
receptors (e.g., TLR-2, TLR-1)[21], NCGS may be more 
of an innate rather than adaptive immune response. 
Since specific triggers are not clear in NCGS, this could 
make NCGS a relatively different pathobiological 
entity from other gluten related conditions like CD and 
WA[20,22]. Changes in the gut microbiome (dysbiosis) 
produced by gluten consumption[23] may also influence 
NCGS. This predominantly innate TLR based systemic 
response potentially incited by changes in microbiota 
was further supported by the increased levels of 
LBP (lipopolysaccharide binding protein) and soluble 
CD14 proteins[24]. Additionally there is evidence for 
NCGS developing in individuals with some genetic 
predispositions (e.g., HLA-DR4, HLA-DR2)[21], which is 
higher than general population but lower than patients 
with CD who have a strong genetic component. 
However, currently this association does not appear to 
be as clear[21,22].
Gluten, the main inciting agent in CD also has a 
significant role in NCGS pathology[25]. In addition to 
gluten, several other food-derived stimuli have been 
shown to also be important in the etiopathogenesis 
of NCGS include alpha amylase/trypsin inhibitors 
(ATIs)[26], FODMAPS[18] and other short chain 
fructans. Gliadin is the alcohol soluble fraction of 
gluten, and contains the bulk of the “immunogenic” 
components[27]. Gliadin has the ability to promote 
an inflammatory response primarily in the upper 
gastrointestinal tract. Gliadin has shown to trigger both 
innate and adaptive response via recruitment of CD4+ 
T cells and increasing expression of interleukin-15 
by enterocytes[28]. The effects of gliadin-induced 
enteric responses are not however completely seen 
in NCGS with innate immune response apparently 
playing a bigger role than adaptive response[21,29]. The 
heterogeneous behavior of NCGS in comparison to CD 
can be explained by different motifs of gliadin protein 
exerting different responses with alpha gliadin peptides 
having a significant role in innate adaptive response, 
and probably expressed more in NCGS individuals[30]. 
NCGS individuals also have increased levels of TLR2 
and to a lesser extent TLR1 expression, increased 
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and immune mediated pathways[32]. The role of gut 
dysbiosis has also recently been emphasized in NCGS 
pathobiology and might help to explain both intestinal 
and non-intestinal manifestations in the disease by 
upregulating gut and systemic inflammation[33].
CLINICAL PRESENTATION
The symptoms of NCGS can occur within hours to 
days following exposure to gluten-containing diet and 
can then dissipate upon withdrawal of gluten. Most of 
the presentation resembles CD, the main similarities 
and differences are presented in Table 1. Frequent 
symptoms reported in NCGS include bloating (87%), 
abdominal pain (83%), epigastric pain (52%), diarrhea 
(50%), and constipation (24%)[8]. Extra-intestinal 
manifestations are also reported which include; lack of 
well-being (68%), tiredness (64%), headache (54%), 
anxiety (39%), “foggy mind” or difficulty focusing 
(38%)[8]. 
Some of the other less commonly reported sym-
ptoms include weight loss, depression and skin rash[8]. 
Unlike CD, nutrient deficiencies such as iron, vitamin D 
and vitamin B 12 deficiencies are not significantly seen 
in NCGS[34]. NCGS also has a lesser association with 
autoimmune disorders when compared with CD[14,35].
number of α and β intraepithelial lymphocytes, and 
reduced number of T-regulatory cells[21]. Solute barrier 
function remains largely unchanged in NCGS, which 
is consistent with fairly normal adaptive immune 
response, normal intestinal permeability and expression 
of tight junction proteins[14,21]. Gluten’s opioid like effect 
on the intestinal transit time and nocebo effect has 
also been studied and may have an important role on 
the overall pathology and clinical presentation of the 
disease[31]. 
In the recent years, other non-gluten components 
of wheat have also been shown to play a major 
role. ATIs in particular, have been implicated in 
NCGS pathology. The role of ATIs in mounting an 
immunological response has been shown in animal 
and human research models and is believed to be 
an important oral antigen both in CD as well as in 
NCGS[26]. This predominantly innate immune response 
involves macrophages, neutrophils and intestinal 
dendritic cells via activation of the toll like receptor 
complexes[21,26]. Their less tendency to affect the 
overall gut morphology falls well in line with NCGS 
pathology. 
The gut microbiota has been shown to play a sig-
nificant role in the pathogenesis of CD, in which gut 
dysbiosis precedes the activation of inflammatory 
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Figure 1  Toll like receptors act as primary sensors to gliadin and non-gluten proteins like alpha amylase/trypsin inhibitors, and microbiota derived signals 
in non-celiac gluten sensitivity. Dysregulated microbiota also release lipopolysaccharide (LPS) in circulation which result in production of LPS-binding protein (LBP) 
from gastrointestinal and hepatic epithelial cells and soluble CD14 (sCD14) from monocytes/macrophages. This leads to activation of transcription factor nuclear 
factor-kappaB (NF-κB), which controls the expression of an array of inflammatory cytokine genes resulting in recruitment of neutrophils and macrophages. In contrast 
to CD, there is limited dendritic cell activation, resulting in reduced expression of Treg cells, reduced FOXP3, TGFβ, IL-10. All these factors with increased expression 
of claudin-4 culminate in reduced intestinal permeability and increased epithelial barrier. Gut dysbiosis can also promote inflammation through expansion of pro-
inflammatory pathobionts. TLRs: Toll like receptors.
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DIAGNOSIS
NCGS should be considered in patients with the history 
and physical examination indicative of a gluten related 
disorder. The clinical presentation of NCGS, as outlined 
earlier, should include the remission of symptoms upon 
withdrawal of gluten. The proposed diagnostic work-up 
includes 3 vital steps.
The 1st step in an NCGS diagnosis is the exclusion 
of CD and WA. The patient needs to be on a GCD for 
a period of 6-wk. Several tests should be performed 
during this period to exclude WA; wheat specific IgE 
and skin prick test, and CD; IgA-tTG, IgG-DGP and 
IgA-EMA. If highly suspicious of CD, the physician 
can proceed with upper endoscopy for duodenal 
biopsy, although this should not be routine testing for 
every patient. If the biopsy results indicate less CD 
probability (Marsh 0-1) then the clinician can proceed 
to the next step[5]. Of note, these tests can be tailored 
by the clinician based on the patients’ presenting 
symptoms. The physician can bypass testing of CD or 
WA and proceed with the work-up for NCGS if patients’ 
history and physical is not suggestive of the condition.
The 2nd step consists of starting the patient on 
a GFD for a period of at least 6 wk and monitoring 
for symptom response. This symptom response is 
evaluated using the gastrointestinal symptom rating 
scale (GSRS) and a numerical rating scale (NRS). 
GSRS is used to identify the symptoms while the NRS 
is used to quantify the symptoms, weekly from week 
0 (baseline) till week 6[36]. A symptomatic response 
to the GFD is defined as a decrease in 30% of the 
baseline score with no worsening of other symptoms in 
at least 50% of the observation time (3 wk)[36]. If the 
patient fails to show an improvement in symptoms in 
6 wk upon resumption of GFD, the diagnosis of NCGS 
is ruled out and other diagnoses such as IBS and other 
functional bowel disorders need to be explored. 
The 3rd step required to confirm the diagnosis 
Igbinedion SO et al. Non-celiac gluten sensitivity
NCGS CD IBS WA
Colonic manifestations Diarrhea Diarrhea Diarrhea Diarrhea
Abdominal pain Abdominal pain Abdominal pain Abdominal pain
Bloating Bloating Bloating Bloating
Constipation Constipation Constipation Constipation
Nausea Nausea Mucous Discharge Nausea




Headache Anemia Major depression Hives
Migraine Osteoporosis Anxiety Angioedema
Foggy mind Neurological disturbances Somatoform disorder Asthma
Fatigue Pubertal delay Fibromyalgia Cough
Eczema like rash Dermatitis herpetiformis Temporomandibular disorder Post Nasal Drip
Myositis Foggy mind Dyspareunia Eczema
Numbness Lymphoma
Psychological changes
Symptom Onset Hours to Days Hours to months Unclear relation to gluten ingestion Minutes to Hours
Cytomorphology Small bowel intraepithelial 
lymphocytosis (Marsh 0-1) 
Villous atrophy with crypt 
hyperplasia
Normal Normal
Biomarkers IgG-AGA IL-17(A) TNF- α IgE antibodies to wheat protein
Zonulin TCR-γδ IELs IL-6




Immunophenotype HLA- DQ2 and DQ8 
genotypes in 50% patients 
HLA- DQ2 and DQ8 
genotypes in 80% patients
Increase in: Transforming growth factor-b 
(TGFb) mutations have been 
associated with higher rates of 
allergic disease
B cells expressing IgG or co-
stimulatory molecules CD80 or 
CD86
T cells  expressing b7 + HLADR+ 
and CD69+
Diagnosis See figure  2 *Serologic testing followed 
by small bowel biopsy
Rome III diagnostic criteria Skin prick test
Presence of serum IGE antibodies 
to wheat protein 
Management GFD GFD Symptomatic treatment and 
elimination of stressors 
GFD
Probiotics Subcutaneous epinephrine for 
any acute episodes
AN-PEP
ICD codes K90.41 K90.0 K58 K52.29
Table 1  Comparison of gluten related disorders[34,51-72]
*4 out of 5 of the following: Typical symptoms of CD, Serum CD IgA class auto antibodies at high titer, HLA-DQ2 and/or HLA-DQ8 genotypes, Celiac 
enteropathy found on small bowel biopsy, Response to a GFD(14).
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of NCGS in patients who respond to treatment with 
the GFD involves the re-introduction of the GCD. 
This is performed because a potential nocebo effect 
(test subjects believe there is a side effect and they 
experience them as a result of this) secondary to the 
exposure to gluten in step 1 cannot be ruled out[37]. 
In this step, the patient is randomly assigned into test 
group x or y. The patient is exposed to either GFD + 
placebo (x) or GFD + gluten (y) for a week. A 1-week 
washout period of strict GFD is observed, followed by 
the crossover to GFD + gluten (x) or GFD + placebo 
(y)[36]. A variation of a 30% symptomatic improvement 
on introduction of the diet free from gluten in test 
group y or a variation of 30% symptomatic appearance 
on introduction of the GCD in test group x (assessed 
by the modified GSRS and NRS scales) indicates a 
positive result. Below this 30% value is considered a 
negative result[36]. This 30% mark is not a scientific 
estimate but is rather a fair estimate of an appropriate 
response[36]. This threshold although used in the 
Salerno experts’ criteria needs scientific validation. 
In step 3, the placebo added should be gluten-
free and must look very similar to the gluten content 
so that both the clinician and the patient are unaware 
of the difference between the gluten and the placebo. 
The dose of gluten to be used for the challenge should 
be close to the average daily intake of gluten (10-15 
g)[38]. The dose should also be easy to mix with the 
gluten carrying package. The package carrying gluten 
can be in any form; bread, muffin. This package 
should also consist of ATIs as well. The suggested 
prepared package should contain 10-15 g of gluten 
and at least 0.3 g of ATIs. The package must also be 
free of FODMAPs[36]. The proposed diagnostic algorithm 
for NCGS is shown in Figure 2.
MANAGEMENT
Currently, the management of NCGS involves a multi-
disciplinary approach. The patient is started on a GFD 
with the help of a registered dietician[14]. A gluten free 
diet usually helps resolve the intestinal and extra-
intestinal symptoms of NCGS. The recommendation 
is to continue adherence to GFD for lifetime. There 
have been few if any studies showing whether or not 
reintroduction of gluten into the diet after a prolonged 
period of being asymptomatic will cause reversion into 
previous symptoms[39]. 
Igbinedion SO et al. Non-celiac gluten sensitivity
Figure 2  Proposed diagnostic algorithm for non-celiac gluten sensitivity. GCD: Gluten containing diet; GFD: Gluten free diet; CD: Celiac disease.
6 weeks 6 weeks 3 weeks
STEP 1                                                 STEP 2                                                  STEP 3
Screening                      Symptom response               Specific diagnosis
Clinical Examination                            GFD for 6 weeks                                DBPC
GCD for 6 weeks                          Exposure to GFD + either
[Gluten (x) or Placebo 
(y)] for 1 week
Serologic evaluation 
(wheat specific serum 
IgE, IgA-tTG, IgG-DGP, 
IgA-EMA) and histologic 
evaluation
Exposure to GFD + 
[Placebo(x) or Gluten 
(y)] for 1 week
Rule out CD and WA
1 week washout
Monitor for symptom 
response    
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The importance of gluten has been outlined in recent 
research. Gluten consumption has been associated 
with a decreased risk of developing type 2 diabetes 
Mellitus and also a decreased risk of coronary heart 
disease[40,41]. Understanding these benefits of gluten 
beyond nutrition reflects the need for caution in the 
use of GFDs in patients without a proven diagnosis of 
NCGS. Although GFD seems to be the most important 
management strategy, it should be suggested only 
after careful examination and a definite diagnosis of 
NCGS. 
Several ongoing clinical trials are now examining 
other possible treatment methods for NCGS besides 
the GFD. One study looks at the use of probiotics 
for alleviation of NCGS symptoms while maintaining 
a gluten free diet with introduction of gluten in a 
controlled environment. This randomized DBPC study 
evaluates NCGS patients’ response to a gluten source 
(two slices of bread each day for 7 d) whilst getting 
probiotics (Bifidobacterium longum ES1 - a patented 
probiotic bacterial strain) or a placebo during that 
time[42]. Theoretically the use of probiotics could result 
in resolving gut dysbiosis by reintroducing gut flora, 
with reduction in both gut and systemic inflammation 
but this needs to be clinically examined. Probiotic 
use has long been a source of debate amongst the 
medical community regarding its exact role as far 
as therapeutic option, it’s essential to see if it can be 
proven to have an ultimate benefit.
Another treatment option under investigation 
is the use of the enzyme Aspergillus niger prolyl 
endoprotease (AN-PEP). It has been reported in 
previous studies that the AN-PEP enzyme significantly 
enhanced gluten digestion in the stomach of healthy 
volunteers[43]. A randomized placebo controlled clinical 
trial is ongoing looking at the effect of AN-PEP on 
gluten degradation in our target population; gluten 
sensitive individuals[44]. If we can apply AN-PEP as a 
means of degrading gluten before it can affect the 
human gut, it would achieve a major goal as patients 
can enjoy foods without worrying about diet restriction, 
worrisome symptoms or soaring food costs. 
The use of ancient diploid wheat species (e.g., 
Triticum monococcum ssp.) as compared with common 
wheat as a new treatment strategy is gaining ground[45]. 
Gianfrani et al[45]. demonstrated the low toxicity of these 
wheat proteins in celiac disease patients following in 
vitro gastrointestinal digestion. Newer studies have 
shown the distinction between these older wheat 
variants and modern wheat[46]. Older wheat variants 
were shown to have lower bioactivity and a lower 
concentration of ATIs in comparison with modern 
wheat[46]. Mechanistically, the modern wheats were 
observed to have high levels of TLR-4-activating ATIs 
which are highly resistant to intestinal proteolysis[46]. 
The application of these studies to favor the use of 
ancient wheat variants in the NCGS population would 
be a major step in the advancement of treatment 
strategies in this disease.
Mayer and Tillisch highlighted the role of the brain-
gut axis in abdominal pain syndromes[47]. Recent 
literature has attempted to further describe how various 
clinical manifestations seen in IBS and also syndromes 
like NCGS could be viewed as a dysregulation in the 
signaling pathway that involves the gut, the enteric 
nervous system and the central nervous system[33,47,48]. 
Newer therapeutic options currently being hypothesized 
in NCGS include the use of vagus nerve stimulation 
and corticotropin releasing factor (CRF) antagonists to 
normalize any possible gut brain dysregulation[33,48]. 
The use of vagus nerve stimulation is based on its 
positive effects on many inflammatory diseases of 
vagus-innervated organs (including the GI tract) which 
thus suggest a case for its application in NCGS[33]. 
The use of CRF antagonists (seen to induce significant 
signal reductions in emotional control centers of the 
brain[23]) is based on the theory that NCGS often has a 
chronic anxiety or stress related component associated 
with the anticipation of abdominal pain. Consequently 
controlling the emotional impact of NCGS may 
improve its symptoms. The several on-going studies/
theories in this area hopefully can shed light on the 
neuropsychiatric therapeutic components of NCGS.
With the release of the updated ICD 10 coding 
system, NCGS, along with WA, IBS and CD each have 
their own codes despite lingering ambiguities about 
NCGS diagnosis/management. NCGS’s code is K90.41 
and it falls under the categories “enteropathy” (code 
K63.9) and gluten sensitivity (Code K90.41). Although 
treatment strategies in NCGS are still evolving, it is 
important to note that NCGS is a specific and billable 
diagnosis for reimbursement purposes[49]. 
CONCLUSION
A recent study involving gastroenterologists showed 
that although most of these specialist physicians 
were able to “identify” NCGS and prescribe GFD for 
its treatment, 44% of them were unable to define or 
agree on a uniform definition[50]. This highlights the 
difficulty in making the diagnosis of NCGS based on 
a specific clinical criterion. NCGS warrants further 
investigation and updated diagnostic and therapeutic 
strategies. 
As we currently stand, the NCGS diagnostic process 
is arduous for the patient, requiring them to be on a 
GCD diet through several parts of the process. This 
could cause distress by eliciting unpleasant symptoms. 
Thus, an alternative diagnostic approach without 
subjecting the patient to the stressor would be a 
significant clinical advancement. Some biomarkers 
identified to aid in the diagnosis of NCGS are IgG-
AGA[15] and Zonulin[51]. However these markers are 
evidently increased in CD as well[15,51]. Establishing 
NCGS specific biomarkers is imminent to also monitor 
for both the resolution of the disease and compliance 
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of the patient to the GFD. Whether NCGS is a transient 
disease or a chronic disease warranting lifetime diet 
restriction still needs to be investigated. 
The lack of information with regards to the prevalence 
of NCGS in the developing world is outstanding. Most of 
the studies being done on this condition are focused on 
the population, which includes the affluent communities 
of Europe and North America. Adhering to the GFD is 
expensive and not easily affordable, the likelihood of a 
low-income patient self-diagnosing as NCGS and going 
on a GFD is very minimal. This warrants the question 
as to if NCGS is really a condition more prevalent in 
the affluent as they are much more conscious of their 
diet intake as well as informed. 
New and evolving science around gluten related 
disorders has led to better understanding of the disease 
process, making it easier for the clinicians to set specific 
management guidelines. Prospective clinical trials in a 
diverse population is warranted to better investigate the 
etiology and progression of this disease. There is still a 
role of further research to better understand NCGS as 
a medical condition.
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